Press enter to begin your search

ValiRx - Signs Letter of Intent to Sub-License VAL201

VAL
Tue, 02 Nov 2021, 17:00 GMT

Dr Suzy Dilly, CEO of ValiRx discusses the recently signed letter of intent with TheoremRx Inc to sub-license ValiRx's legacy asset VAL201.

Dr Suzanne Dilly
Chief Executive Officer
VAL
618169a029c8b82a5a01e169
SHOW MORE
FROM THIS COMPANY
ValiRx - Signs Letter of Intent to Sub-License VAL201
VAL Tue, 02 Nov 2021, 17:00 GMT

ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.

Industry: Health Care

Contact: +44 (0)2476 796496
Barling Way
https://www.valirx.com/

Dr Suzy Dilly, CEO of ValiRx discusses the recently signed letter of intent with TheoremRx Inc to sub-license ValiRx's legacy asset VAL201.

Dr Suzanne Dilly
Chief Executive Officer
POWERED BY